Athira Pharma, Inc.
NASDAQ:ATHA
0.54 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Athira Pharma, Inc. |
Symbool | ATHA |
Munteenheid | USD |
Prijs | 0.542 |
Beurswaarde | 20,958,652 |
Dividendpercentage | 0% |
52-weken bereik | 0.412 - 4.298 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mark J. Litton M.B.A., MBA, Ph.D. |
Website | https://www.athira.com |
An error occurred while fetching data.
Over Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)